Symptoms of postural orthostatic tachycardia syndrome in pregnancy: a cross-sectional, community-based survey
This article includes Author Insights, a video abstract available at: https://players.brightcove.net/3806881048001/default_default/index.html?videoId=6319977749112
Abstract
Objective
To evaluate the relationship between postural orthostatic tachycardia syndrome (POTS) and pregnancy.
Design
Cross-sectional survey.
Setting
International.
Sample
A total of 8941 female patients with a diagnosis of POTS.
Methods
Data from the survey were analysed using descriptive measures and stratified for comparisons.
Main outcome measures
Symptom course of POTS during pregnancy. Secondary outcomes included pregnancy loss, POTS onset during pregnancy and the impacts of a comorbid diagnosis of Ehlers–Danlos syndrome or an autoimmune disorder on symptoms during pregnancy.
Results
Overall, 40.8% (n = 3652) of participants reported one or more pregnancies. Most participants experienced worsening of symptoms in the first (62.6%) and third (58.9%) trimesters and 3 months after pregnancy (58.7%), and 81.1% experienced worsening symptoms at any point in their pregnancy. Most participants with worsening symptoms in the first trimester also experienced worsening symptoms in the second (61.6%) and third (68.1%) trimesters, but if they improved in the first trimester then this improvement persisted in the second and third trimesters. Of participants who reported that POTS was triggered by a specific event (41.3%), 8.1% reported pregnancy as the trigger for the onset.
Conclusions
Postural orthostatic tachycardia syndrome symptoms in the first trimester of pregnancy may help predict symptom course throughout the duration of pregnancy. Some individuals may experience an initial onset of POTS during pregnancy. This novel information may guide clinicians in counselling patients with POTS who are planning pregnancy.
CONFLICT OF INTERESTS STATEMENT
KMB, KAN, LES, CAS, LEO, EMG, AG, AD, AJK and PSG, have no conflicts of interest to report. AP is a consultant for Alnylam, Catalyst, and Argenx. IB is a consultant for Theravance Biopharma Inc., Ammeal Pharmaceuticals, Regeneron, and Takeda Pharmaceutical. RSS is a Cardiac Arrhythmia Network of Canada (CANet) Network Investigator. SRR is a consultant for Lundbeck NA Ltd.Theravance Biopharma Inc., Amneal Pharma, Servier Affaires Medicales, Regeneron, and argenx BV, is the chair for the Data Safety and Monitoring Board for Arena Pharmaceuticals, is a CANet Network Investigator, and is a member of the Medical Advisory Board of Dysautonomia International and PoTS UK, both without financial compensation. Completed disclosure of interests form available to view online as supporting information.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in the supporting information for this article.